methotrexate has been researched along with Lymphoma, Mantle-Cell in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (32.14) | 29.6817 |
| 2010's | 14 (50.00) | 24.3611 |
| 2020's | 5 (17.86) | 2.80 |
| Authors | Studies |
|---|---|
| Badillo, M; Fayad, L; Feng, L; Flowers, CR; Fowler, N; Hagemeister, FB; Hill, HA; Iyer, SP; Jain, P; Jorgensen, J; Kanagal-Shamanna, R; Lee, HJ; Li, S; Lin, P; Medeiros, LJ; Nair, R; Nastoupil, L; Navsaria, L; Nogueras Gonzalez, GM; Ok, CY; Patel, KP; Samaniego, F; Santos, D; Steiner, R; Tang, G; Thirumurthi, S; Vega, F; Wagner-Bartak, N; Wang, L; Wang, ML; Wang, SA; Westin, JR; Xu, G; Xuelin, H; Yao, Y; Yin, CC; Zhao, S | 1 |
| Aldrees, S; Jeeva-Patel, T; Margolin, E | 1 |
| Angrilli, F; Federico, M; Galimberti, S; Luminari, S; Manni, M; Marcheselli, L; Massaro, F; Merli, F; Petrini, M; Stelitano, C; Stepanishyna, Y; Tecchio, C; Visco, C | 1 |
| Alderuccio, JP; Alencar, AJ; Iyer, SG; Lossos, IS; Reis, IM; Rosenblatt, JD; Saul, EE | 1 |
| Algarra-Algarra, JL; Gómez-Catalán, I; Hernández-Fernández, F; Ibañez-García, Á; Marín-Sánchez, A; Martínez-Fernández, G; Montoya-Morcillo, MC; Romero-Macías, JR | 1 |
| Fanale, M; Fayad, LE; Feng, L; Ford, P; Fowler, N; Goy, A; Hagemeister, F; Hartig, K; Kantarjian, HM; Kwak, LW; McLaughlin, P; Medeiros, LJ; Naig, A; Neelapu, S; Oki, Y; Orlowski, R; Pro, B; Rodriguez, MA; Romaguera, JE; Samaniego, F; Smith, J; Valentinetti, M; Wang, M; Younes, A | 1 |
| Kawedia, JD; Myers, AL; Nader, A; Shank, BR; Westin, JR | 1 |
| Bernstein, SH; Burack, R; Cebula, E; Epner, E; Fisher, RI; Leblanc, M; Miller, TP; Rimsza, L; Unger, JM | 1 |
| Aláez, C; Arranz, E; Arranz, R; Caballero, D; Canales, MA; Cannata-Ortiz, J; Conde, E; García-Marco, JA; García-Noblejas, A; Grande, C; Martín, A; Martínez-Sánchez, P; Pérez-Calvo, J; Salar, A; Sánchez, JJ; Sánchez-González, B; Terol, MJ | 1 |
| Bertoni, F; Cavalli, F; Conconi, A; de Campos, CP; Franceschetti, S; Gaidano, G; Ghielmini, M; Margiotta Casaluci, G; Stathis, A; Stussi, G; von Hohenstaufen, KA; Zucca, E | 1 |
| Barbara, JA; Khow, KS; Kuss, BJ; Li, JY; Yong, AS; Yong, TY | 1 |
| Cabanillas, F; Cheah, CY; Chihara, D; Fayad, LE; Goy, A; Hagemeister, FB; Kantarjian, H; Kwak, LW; McLaughlin, P; Pro, B; Rodriguez, MA; Romaguera, JE; Samaniego, F; Wang, ML; Westin, JR; Younes, A | 1 |
| Barr, PM; Bernstein, SH; Blum, KA; Cashen, AF; Chen, RW; Cheson, BD; Constine, L; Faham, M; Fenske, TS; Fisher, RI; Forman, SJ; Friedberg, JW; Kahl, BS; Kahwash, S; Leblanc, M; Leonard, JP; Li, H; Phillips, T; Rimsza, LM; Shea, TC; Smith, SM; Wilkins, J | 1 |
| Ahn, HK; Chang, MH; Kim, SJ; Kim, WS; Lee, SJ; Yi, JH | 1 |
| Cabanillas, F; Fayad, L; Hagemeister, F; Kantarjian, H; Kwak, LW; McLaughlin, P; Rodriguez, MA; Romaguera, J; Wang, M; Zhou, Y | 1 |
| Garcia, M; Inamdar, KV; Medeiros, LJ; Rassidakis, GZ; Romaguera, JE | 1 |
| Khouri, IF; Tam, CS | 1 |
| Drakos, E; Garcia, M; Inamdar, KV; Knoblock, RJ; Leventaki, V; Medeiros, LJ; Rassidakis, GZ; Romaguera, JE | 1 |
| Byrne, GE; Coleman, F; Escalón, MP; Hosein, PJ; Lossos, IS; Morgensztern, D; Rosenblatt, JD; Walker, GR | 1 |
| Cabanillas, F; Fayad, LE; Feng, L; Goy, A; Hagemeister, FB; Hartig, K; Kantarjian, H; Kwak, L; McLaughlin, P; Pro, B; Rodriguez, MA; Romaguera, JE; Samaniego, F; Wang, M; Weaver, P; Younes, A | 1 |
| Fayad, LE; Feldman, T; Ford, P; Goldberg, S; Goy, A; Hartig, K; Kwak, LW; McLaughlin, P; Pecora, A; Pro, B; Rodriguez, A; Romaguera, JE; Smith, J; Wang, M; Weaver, P | 1 |
| Andresen, S; Bolwell, BJ; Copelan, E; Dean, R; Hill, BT; Kalaycio, M; Pohlman, B; Rybicki, L; Smith, S; Sobecks, R; Sweetenham, J; Tench, S | 1 |
| Ambrosetti, A; Angrilli, F; Barbolini, E; Capodanno, I; Caracciolo, F; Carella, AM; Di Renzo, N; Federico, M; Galimberti, S; Ilariucci, F; Luminari, S; Merli, F; Petrini, M; Stelitano, C; Visco, C | 1 |
| Vose, JM | 1 |
| Hino, N; Ishibashi, K; Kanaji, N; Uno, H | 1 |
| Bosch, F; Campo, E; Ferrer, A; Graus, F; Gutiérrez, G; López-Guillermo, A; Mercadal, S; Montserrat, E; Rozman, C; Rozman, M; Villamor, N | 1 |
| Boyle, R; Cheung, C; Dua, U; Gandhi, MK; Gill, D; Nourse, J; Tran, H | 1 |
| Benedetti, F; Bordignon, C; Bregni, M; Ciceri, F; Corradini, P; Dodero, A; Falda, M; Gianni, AM; Ladetto, M; Lucesole, M; Olivieri, A; Pileri, A; Rambaldi, A; Sajeva, MR; Tarella, C; Tresoldi, M; Voena, C; Zallio, F | 1 |
3 review(s) available for methotrexate and Lymphoma, Mantle-Cell
| Article | Year |
|---|---|
Autologous and allogeneic stem cell transplantation: rising therapeutic promise for mantle cell lymphoma.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prednisone; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vincristine | 2009 |
Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma.
Topics: Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Cell Proliferation; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Epidemiologic Methods; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Methotrexate; Middle Aged; Rituximab; Treatment Outcome; Vincristine | 2010 |
Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Asymptomatic Diseases; Biomarkers, Tumor; Bone Marrow Examination; Chemoradiotherapy; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 14; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Management; Doxorubicin; Female; Genes, bcl-1; Humans; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Risk Assessment; Rituximab; Salvage Therapy; Stem Cell Transplantation; Translocation, Genetic; Vincristine | 2012 |
13 trial(s) available for methotrexate and Lymphoma, Mantle-Cell
| Article | Year |
|---|---|
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.
Topics: Adenine; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Humans; Lymphoma, Mantle-Cell; Lymphopenia; Methotrexate; Middle Aged; Piperidines; Rituximab; Thrombocytopenia; Treatment Outcome; Vincristine | 2022 |
Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Rituximab; Stem Cell Transplantation; Survival Rate; Vincristine | 2021 |
R-MACLO-IVAM regimen followed by maintenance therapy induces durable remissions in untreated mantle cell lymphoma - Long term follow up results.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Male; Methotrexate; Middle Aged; Progression-Free Survival; Prospective Studies; Remission Induction; Rituximab; Thalidomide; Vincristine; Young Adult | 2021 |
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chemotherapy-Induced Febrile Neutropenia; Cyclophosphamide; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Incidence; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Rituximab; Survival Rate; Time Factors; Treatment Failure; Vincristine | 2018 |
A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Rituximab; Survival Rate; Treatment Outcome; Vincristine | 2013 |
First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELT
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Pilot Projects; Prospective Studies; Rituximab; Treatment Outcome | 2013 |
Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Rituximab; Vincristine | 2016 |
RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Remission Induction; Rituximab; Transplantation, Autologous; Treatment Outcome; Vincristine; Young Adult | 2017 |
Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Recurrence; Rituximab; Salvage Therapy; Vincristine | 2008 |
High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Remission Induction; Rituximab; Thalidomide; Treatment Outcome; Vincristine | 2010 |
Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma.
Topics: Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Cell Proliferation; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Epidemiologic Methods; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Methotrexate; Middle Aged; Rituximab; Treatment Outcome; Vincristine | 2010 |
Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma.
Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Pyrazines; Rituximab; Vincristine | 2010 |
Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Follow-Up Studies; Genetic Markers; Hematologic Diseases; Humans; Infections; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Methotrexate; Middle Aged; Prospective Studies; Rituximab; Treatment Outcome; Vincristine; Young Adult | 2012 |
13 other study(ies) available for methotrexate and Lymphoma, Mantle-Cell
| Article | Year |
|---|---|
Bilateral Infiltrative Optic Neuropathy of Systemic Mantle Cell Lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Central Nervous System Neoplasms; Cytarabine; Fundus Oculi; Humans; Lymphoma, Mantle-Cell; Male; Methotrexate; Optic Nerve; Optic Nerve Diseases; Rituximab | 2020 |
Efficacy of chemotherapy protocols for hematological malignancies: H-CVAD versus GELA/BURKIMAB/PETHEMA LAL.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Hematologic Neoplasms; Humans; Lymphoma, Mantle-Cell; Male; Mercaptopurine; Methotrexate; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Retrospective Studies; Treatment Outcome; Vincristine; Young Adult | 2021 |
A rare case of methotrexate and primaquine co-administration in a mantle cell lymphoma patient.
Topics: Aged; Antimetabolites, Antineoplastic; Humans; Lymphoma, Mantle-Cell; Male; Methotrexate; Primaquine | 2019 |
Prognostic impact of monocyte count at presentation in mantle cell lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Humans; Italy; Kaplan-Meier Estimate; Leukocyte Count; Leukocytes; Lymphatic Irradiation; Lymphocytes; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Monocytes; Prednisolone; Prednisone; Prognosis; Proportional Hazards Models; Risk; Splenectomy; Stem Cell Transplantation; Switzerland; Transplantation, Autologous; Treatment Outcome; Vincristine | 2013 |
Minimal change disease associated with newly diagnosed mantle cell lymphoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Glucocorticoids; Humans; Lymphoma, Mantle-Cell; Methotrexate; Middle Aged; Nephrosis, Lipoid; Nephrotic Syndrome; Prednisolone; Prednisone; Vincristine | 2014 |
Rituximab-induced acute thrombocytopenia: a case report and review of the literature.
Topics: Acute Disease; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Humans; Immunophenotyping; Infusions, Parenteral; L-Lactate Dehydrogenase; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Platelet Count; Rituximab; Splenomegaly; Thrombocytopenia; Vincristine | 2009 |
Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Ki-67 Antigen; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Prognosis; Rituximab; Survival Analysis; Vincristine | 2009 |
Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Administration Schedule; Eukaryotic Initiation Factor-4E; Female; Humans; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Prognosis; Rituximab; Survival Analysis; Treatment Outcome; Vincristine | 2009 |
Treatment with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate results in poor mobilization of peripheral blood stem cells in patients with mantle cell lymphoma.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Leukapheresis; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Time Factors; Transplantation, Autologous; Treatment Outcome; Vincristine | 2011 |
[A patient with mantle cell lymphoma who successfully underwent auto-PBSCT in combination with in vivo purging of tumor cells using rituximab].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Purging; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Lymphoma, Mantle-Cell; Methotrexate; Middle Aged; Prednisone; Remission Induction; Rituximab; Transplantation, Autologous; Vincristine | 2002 |
Central nervous system involvement in mantle cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cerebrospinal Fluid; Chlorambucil; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Injections, Spinal; Lymphocytosis; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Prednisolone; Prognosis; Risk; Severity of Illness Index; Vincristine | 2008 |
Methotrexate-associated mantle-cell lymphoma in an elderly man with myasthenia gravis.
Topics: Aged; Diagnosis, Differential; Humans; Immunosuppressive Agents; Lymphocytes; Lymphocytosis; Lymphoma, Mantle-Cell; Male; Methotrexate; Myasthenia Gravis; Risk Factors | 2008 |
Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies.
Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Transfusion; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Polymerase Chain Reaction; Recurrence; Remission Induction; Survival Rate; Thiotepa; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2002 |